Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Rituximab-related late-onset neutropenia in a patient with severe rheumatoid arthritis.

× No keyword cloud information.

7 in total

1. Rituximab efficiency in children with steroid-dependent nephrotic syndrome.

Authors: Anne-Laure Sellier-Leclerc; Marie-Alice Macher; Chantal Loirat; Valérie Guérin; Hervé Watier; Michel Peuchmaur; Véronique Baudouin; Georges Deschênes
Journal: Pediatr Nephrol Date: 2010-03-18 Impact factor: 3.714

2. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis.

Authors: Maya H Buch; Josef S Smolen; Neil Betteridge; Ferdinand C Breedveld; Gerd Burmester; Thomas Dörner; Gianfranco Ferraccioli; Jacques-Eric Gottenberg; John Isaacs; Tore K Kvien; Xavier Mariette; Emilio Martin-Mola; Karel Pavelka; Paul P Tak; Desiree van der Heijde; Ronald F van Vollenhoven; Paul Emery
Journal: Ann Rheum Dis Date: 2011-03-06 Impact factor: 19.103

3. Immunoglobulin G Fc receptor FcgammaRIIIa 158 V/F polymorphism correlates with rituximab-induced neutropenia after autologous transplantation in patients with non-Hodgkin's lymphoma.

Authors: Wen-Kai Weng; Robert S Negrin; Philip Lavori; Sandra J Horning
Journal: J Clin Oncol Date: 2009-11-23 Impact factor: 44.544

4. Fulminant viral myocarditis after rituximab therapy in pediatric nephrotic syndrome.

Authors: Anne-Laure Sellier-Leclerc; Emre Belli; Valérie Guérin; Peter Dorfmüller; Georges Deschênes
Journal: Pediatr Nephrol Date: 2013-05-23 Impact factor: 3.714

5. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial.

Authors: Joan T Merrill; C Michael Neuwelt; Daniel J Wallace; Joseph C Shanahan; Kevin M Latinis; James C Oates; Tammy O Utset; Caroline Gordon; David A Isenberg; Hsin-Ju Hsieh; David Zhang; Paul G Brunetta
Journal: Arthritis Rheum Date: 2010-01

Review 6. Update on the use of rituximab for intractable rheumatoid arthritis.

Authors: R John Looney
Journal: Open Access Rheumatol Date: 2009-06-26

Review 7. Agranulocytosis under biotherapy in rheumatoid arthritis: three cases hypothesis of parvovirus B19 involvement in agranulocytosis observed under tocilizumab and rituximab for the treatment of rheumatoid arthritis.

Authors: C Giraud; Z Tatar; M Soubrier
Journal: Clin Rheumatol Date: 2016-08-19 Impact factor: 2.980

7 in total